MGNX — MacroGenics, Inc.

Is MGNX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

MacroGenics, Inc. (MGNX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $4.09. The rating moved from Neutral to Overbought on August 18, 2026.

See all overbought Healthcare stocks →

AI analysis

MacroGenics, Inc. is a clinical‑stage biologics company with differentiated antibody/Fc engineering assets and upside tied to upcoming development milestones and partner activity. The stock benefits from broader biologics and CDMO demand and any successful collaborations or positive clinical signals, while downside is concentrated in binary clinical/regulatory outcomes and the need for additional capital to fund operations. Near‑term performance will track clinical newsflow, partnership progress, and small‑cap biotech sentiment; liquidity and execution on financing or dealmaking are key determinants of the medium‑term trajectory.

Key factors

  • Pipeline-stage biologics and immuno‑oncology programs with demonstrated scientific rationale that provide upside tied to clinical readouts and partner deals.
  • Sector tailwinds for biologics, CDMO/CRO demand and specialty biologic commercial markets that can increase partnering and manufacturing economics.
  • Existing collaborations and licensing potential that can provide non‑dilutive revenue or milestone upside if executed.
  • Manageable near‑term market environment (risk‑on tone) supporting small‑cap biotech sentiment for growth/high‑risk stories.
  • Expertise in antibody engineering and Fc‑platform technologies that differentiate assets versus some competitors.
  • Cash runway and capital strategy uncertainty: ability to fund trials or secure partnership financing will materially influence value realization.

Risks

  • Clinical trial failures or delayed readouts for key development candidates, which would materially reduce valuation.
  • High cash burn and likely future financing or dilution if partnerships/milestones do not provide timely funding.
  • Intense competition from larger biotech and pharma companies in oncology and immunology, including competing mechanisms and faster development pathways.
  • Regulatory risk around trial design, endpoints and approvals that could extend timelines or require costly additional studies.
  • Dependence on third‑party manufacturing, CROs and partners — execution issues can delay development and commercialization.
  • Market and sentiment sensitivity: as a small biotech, price is vulnerable to macro liquidity shifts, sector rotations, and headline-driven volatility.

See today's live rating, score and targets

Members see the live hourly rating for MGNX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.